Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00323414 · ClinicalTrials.gov registry record · Phase 2
Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver
A Phase 2 study of Fatty Liver, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 2
- Study locations
NCT00323414: Completed Phase 2 study of Fatty Liver, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT00323414 is a Phase 2 study of Fatty Liver that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 37 participants, below the 209-participant average among 20 other Fatty Liver trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00323414, a Phase 2 study of Fatty Liver, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 2
- Study locations
Study Summary
Non-alcoholic steatohepatitis (NASH), the most severe form of liver injury in the spectrum of non-alcoholic fatty liver disease (NAFLD), has emerged as the major cause of chronic liver disease in developed countries. Among adults in the United States, the prevalence is between 5.7% and 17%. These rates are expected to increase concurrent with the epidemics of obesity and type 2 diabetes mellitus, which are the major risk factors for NAFLD and NASH. In addition to its high prevalence, NASH is also a progressive fibrotic disease that advances to cirrhosis and liver related death in 20% and 12% of patients, respectively. Among NASH patients with cirrhosis, 40% have liver related death. Diabetics are particularly prone to experience these poor outcomes. No therapy has been proven effective for patients with NASH. The purpose of this study is to find out whether treatment with polyunsaturated fatty acids (eicosapentaenoic acid \[EPA\] combined with docosahexaenoic acid \[DHA\] called Opti-EPA) improves NASH compared to treatment with placebo pills. The placebo pills will contain corn oil and will be contained in a capsule, but have no medical effect on the body. The investigators will determine improvement in NASH from microscopic changes in the subject's liver tissue during 48 weeks of treatment. This means that the subject will need to have a liver biopsy before and after the treatment. Omega-3 fatty acids are a form of polyunsaturated fats, one of the four basic types of fat that the body gets from food. (Cholesterol, saturated fat, and monounsaturated fat are the others.) One's body does not make this type of fat; it comes from food sources. These fats are found in foods like cold water fish (tuna, salmon, and mackerel), and vegetable products like flaxseed oil and walnuts. Research shows that polyunsaturated fats are good for people. Studies have shown that it is good for heart health by playing a role in keeping blood cholesterol levels low, keeping irregular he
Primary Outcome
The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) is a score based on the liver biopsy. It represents the sum of scores for steatosis, lobular inflammation, and ballooning, and ranges from 0-8, with high scores indicating more activity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Polyunsaturated fatty acid (Opti-EPA)
Study Locations (2)
Ohio
- MetroHealth Medical Center - Cleveland
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2006-04 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT00323414 record still lists
NCT00323414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 209-participant average among 20 other Fatty Liver trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Fatty Liver appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00323414 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00323414 about?
NCT00323414 is a clinical study titled "Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver". Non-alcoholic steatohepatitis (NASH), the most severe form of liver injury in the spectrum of non-alcoholic fatty liver disease (NAFLD), has emerged as the major cause of chronic liver disease in developed countries. Among adults in the United States, the prevalence is between 5.7% and 17%. These ra...
What is the current status of trial NCT00323414?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2006-04. Estimated completion is 2011-12.
What conditions does trial NCT00323414 study?
This clinical trial studies the following conditions: Fatty Liver.
What interventions are being tested in trial NCT00323414?
The interventions under investigation include: Placebo (DRUG), Polyunsaturated fatty acid (Opti-EPA) (DRUG).
Who is sponsoring clinical trial NCT00323414?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00323414 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fatty Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00323414's enrollment target sits among peer trials
37 14th of 20 higher than 7 of 20 other Fatty Liver trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fatty Liver trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
ACTIVE NOT RECRUITING · Phase 2
-
An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis
COMPLETED · Phase 2
-
Intermittent Fasting for NAFLD in Adults
RECRUITING · NA
-
Early Tracking of Childhood Health Determinants (ETCHED) Study
RECRUITING
-
Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population
RECRUITING
-
Blood Collection Biorepository for Liver Disease Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia